Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Make a selection below to explore our full database of 3 results matching: "K Saag"
ACE Reports
(3 Reports)
ACE Reports
Our AI driven High Impact metric predicts an article's future number of citations by considering the content of the article.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Open Advanced Search
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
General Orthopaedics
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
J Bone Miner Res. 2022 01-Dec;():. 10.1002/jbmr.4719
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
J Bone Miner Res. 2022 01-Dec;():. 10.1002/jbmr.4719
Metabolic Disorders
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
N Engl J Med. 2007 Nov 15;357(20):2028-39
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
N Engl J Med. 2007 Nov 15;357(20):2028-39
Metabolic Disorders
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
Lancet. 2009 Apr 11;373(9671):1253-63
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
This report has been verified by one or more authors of the original publication.
Lancet. 2009 Apr 11;373(9671):1253-63